ABSTRACT
Lung injury is a major determinant of survival after pediatric hematopoietic cell transplantation (HCT). A deeper understanding of the relationship between pulmonary microbes, immunity, and the lung epithelium is needed to improve outcomes. In this multicenter study, we collected 278 bronchoalveolar lavage (BAL) samples from 229 patients treated at 32 children’s hospitals between 2014-2022. Using paired metatranscriptomes and human gene expression data, we identified 4 patient clusters with varying BAL composition. Among those requiring respiratory support prior to sampling, in-hospital mortality varied from 22-60% depending on the cluster (p=0.007). The most common patient subtype, Cluster 1, showed a moderate quantity and high diversity of commensal microbes with robust metabolic activity, low rates of infection, gene expression indicating alveolar macrophage predominance, and low mortality. The second most common cluster showed a very high burden of airway microbes, gene expression enriched for neutrophil signaling, frequent bacterial infections, and moderate mortality. Cluster 3 showed significant depletion of commensal microbes, a loss of biodiversity, gene expression indicative of fibroproliferative pathways, increased viral and fungal pathogens, and high mortality. Finally, Cluster 4 showed profound microbiome depletion with enrichment of Staphylococci and viruses, gene expression driven by lymphocyte activation and cellular injury, and the highest mortality. BAL clusters were modeled with a random forest classifier and reproduced in a geographically distinct validation cohort of 57 patients from The Netherlands, recapitulating similar cluster-based mortality differences (p=0.022). Degree of antibiotic exposure was strongly associated with depletion of BAL microbes and enrichment of fungi. Potential pathogens were parsed from all detected microbes by analyzing each BAL microbe relative to the overall microbiome composition, which yielded increased sensitivity for numerous previously occult pathogens. These findings support personalized interpretation of the pulmonary microenvironment in pediatric HCT, which may facilitate biology-targeted interventions to improve outcomes.
Competing Interest Statement
DISCLOSURES: M.S.Z. discloses consulting and advisory board work (Sobi). C.C.D. discloses consulting and advisory board work (Jazz Pharmaceuticals; Alexion Inc.). J.J.A. discloses consulting and advisory board work (AscellaHealth; Takeda). T.C.Q. discloses consulting and advisory board work (Alexion AstraZeneca Rare Disease; Jazz Pharmaceuticals). H.A-A. discloses research support (Adaptive). R.P. discloses consulting and advisory board work (BlueBird Bio) and research support (Amgen). M.A.P. discloses consulting and advisory board work (Novartis; Pfizer; Cargo; BlueBird Bio; Vertex) and research support (Miltenyi; Adaptive). L.N.S. discloses consulting and advisory board work (Sanofi). J.J.B. discloses consulting and advisory board work (Sanofi; BlueRock; Sobi; SmartImmune; Immusoft; Advanced Clinical; Merck). J.L.D. discloses salary support and research support (Chan Zuckerberg Biohub).
Funding Statement
ACKNOWLEDGEMENTS: M.S.Z. received research funding from NHLBI K23HL146936, NICHD K12HD000850, the American Thoracic Society, the Pediatric Transplantation and Cell Therapy Foundation, and the National Marrow Donor Program Amy Strelzer Manasevit Grant. M.Y.M received research funding from NCI F31CA271571. H.A-A. received grant funding from the Gateway Foundation and St. Baldrick's Foundation. J.S.K. and J.J.B. received research funding from NCI P30CA008748. M.A.P. received research funding from NCI P30CA040214. L.N.S. received research funding from NIGMS R21GM147800, NCI R37CA244775, and NCI U2CCA271890. J.L.D. received research funding from the Chan Zuckerberg Biohub. Additional funding for the study was provided by NHLBI UG1HL069254 and a Johnny Crisstopher Children's Charitable Foundation St. Baldrick's Consortium Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of California, San Francisco Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* PTCTC Investigators Listed in eTable 1.
